top of page


Started in 2011, Proteovista develops innovative enabling technologies and research tools to address a key area of drug discovery in cancer and heart disease.

  • Our novel high throughput technologies based on the SNAP platform, uniquely targets the interactions between disease-related proteins and their DNA sites at specific genes using DNA-directed small molecules.

  • By focusing on drug targets at precise DNA sites, our approach opens novel avenues for drug discovery while alleviating the wide-spread and deleterious side effects that often occur with currently available therapeutics.  

We also offer custom microarray services, bioinformatics solutions, assay development, and DNA sequence specificity determination using our SNAP technology, fluorescence polarization, and TR-FRET.

Mary S. Ozers PhD
Founding Team & Chief Scientific Officer

Mary is the Co-Founder and Chief Scientific Officer of Proteovista and has been a Principal Investigator on 9 grants in both industrial and academic settings. Previously, she was a Group Leader at Panvera/Invitrogen, producing over 500 recombinant proteins for drug discovery assay development and lead developer for the fluorescence-based nuclear receptor-coactivator interaction assays. Mary was in the Integrated Science Program (ISP) and earned a B.A. in Biochemistry, Molecular Biology, and Cell Biology from Northwestern University, and a PhD in Biochemistry from the University of Wisconsin-Madison training with Jack Gorski, who discovered the estrogen receptor. Mary also holds an adjunct position in Oncology at the University of Wisconsin-Madison.

Christopher L. Warren PhD
Founding Team & Chief Biotechnology Officer

Chris co-founded Proteovista and has been a Principal Investigator on five of the company grants from the National Institutes of Health. He has designed and developed off-shoots of the SNAP technology, including methods to identify DNA and RNA aptamers to proteins. He has extensive data analysis experience and has developed methods (e.g. Sequence Specificity Landscapes) to computationally and visually interpret high dimensional protein-DNA interaction data sets. He served as the primary biostatistician for clinical trials at the University of Wisconsin-Madison, Dept of Anesthesiology. Chris earned a B.A. in Biochemistry and in the Integrated Science Program (ISP) from Northwestern University. He received his PhD in Biochemistry from  UW-Madison and completed a fellowship in Computation and Informatics in Biology and Medicine (CIBM).

We thank our former employees: Matt Rodesch MS (Senior Scientist), Steven Riddle MS (Scientist), Hillary St. John PhD (Post-doctoral Associate), Jennifer M. Gagne PhD (Senior Scientist), Mika Miyamoto (summer intern), and Courtney Krueger BS (Associate Scientist) for their contributions to Proteovista!

bottom of page